英夫利昔单抗治疗炎症性肠病后诱发银屑病的研究进展

Research progress of psoriasis induced by Infliximab in the treatment of inflammatory bowel disease

英夫利昔单抗(IFX)是针对肿瘤坏死因子-α的嵌合人鼠单克隆免疫球蛋G1抗体,在我国已被广泛应用于炎症性肠病(IBD)及银屑病的治疗,且疗效显著。然而,有意思的是,近年来IFX治疗IBD后诱发、加重银屑病的报道逐渐增多,在IBD的基础上并发银屑病,进一步加重患者病情,IFX相关性银屑病的发病特点、发病机制、临床诊疗等问题亟待解决。在IBD的治疗中,IFX相关性银屑病的发病机制可能与免疫、遗传、IFX血药浓度等因素有关,本文旨在对IFX应用于IBD后诱发银屑病的研究进展作一综述。

Infliximab(IFX)is a monoclonal immunoglobulin G1 antibody against tumor necrosis factor-αwhich has been widely used in the treatment of inflammatory bowel disease(IBD)and psoriasis in China,and the effect is remarkable.It is interesting to note that in recent years,the reports of psoriasis induced by IFX in IBD have gradually increased.Psoriasis,as the complication of IBD,aggravates the patients′suffering,and its characteristics,pathogenesis,prevention,diagnosis,treatment are urgently needed to be solved.In the treatment of IBD,the pathogenesis of psoriasis may be related to immune,genetic,IFX concentration and other factors.A review was performed to provide information about the research progress of psoriasis induced by IFX in IBD.